Antibody drug conjugate (ADC)

Woman reading on a tablet
#2023 #Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Biotech hubs #Cell and gene therapy #CRISPR #Diversity #Oncology #Regulatory

DDW top reads in 2023

DDW’s Senior Digital Content Editor Diana Spencer reviews the year’s top ten articles. DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a… Read More

#Exclusive Content

Bladder cancer
#Antibody drug conjugate (ADC) #Astellas Pharma #Bladder cancer #FDA #Oncology #Pfizer #Phase III trial

Bladder cancer therapy reduces risk of death by 50%

The US Food and Drug Administration (FDA) has approved antibody-drug conjugate (ADC) enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer (la/mUC). The approval is based on clinical data which found that Padcev plus pembrolizumab nearly doubled median overall survival compared to… Read More

#Editor's Choice #News #Regulatory

Breast cancer research
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #Clinical trials #Oncology

The latest advances in breast cancer therapy

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including… Read More

#Cancer Research #News #Trending News

Antibodies
#Antibodies #Antibody discovery workflow #Antibody drug conjugate (ADC) #CAR-T #Therapeutic Antibodies

Fortis Life Sciences leads the way in custom antibody discovery

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. Fortis Life Sciences offers… Read More

#News

Lisbon skyline
#Antibodies #Antibody drug conjugate (ADC) #Biochemistry #Biologics #Biologics / Biotechnology #Bispecific Antibodies #Combination therapy #Engineered antibodies #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 1

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Cell therapy #Drug discovery #Immunology / Virology & Vaccines #Phase I trial

New DDW Highlights podcast: 30 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week feature a variety of treatment approaches, from… Read More

#News

#Antibody drug conjugate (ADC) #Cell therapy #Drug discovery #Immunology / Virology & Vaccines #Phase I trial

This week in drug discovery (23-27 October)  

News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer. My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Iksuda Therapeutics #Oncology #Phase I trial #Solid tumours

First patient dosed with antibody drug conjugate for HER2+ tumours

Iksuda Therapeutics has dosed the first patient in a Phase I trial of antibody drug conjugate (ADC) IKS014 in patients with advanced solid tumours that express HER2. This follows positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through… Read More

#Cancer Research #News

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

New DDW Highlights podcast: 2 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Immunotherapy has taken centre stage this week, with several announcements relating to… Read More

#News

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

This week in drug discovery (25-29 September)  

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo… Read More

#News

#Antibody drug conjugate (ADC) #Cancer research #FDA #Mythic Therapeutics #Non-small cell lung cancer (NSCLC)

FDA fast-tracks ADC for non-small cell lung cancer 

The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression. The designation for Mythic, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Genmab #Oncology #Phase III trial #Seagen

Antibody-drug conjugate extends overall survival in cervical cancer

In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An independent data monitoring committee determined that OS crossed… Read More

#Cancer Research #News

#Antibodies #Antibody drug conjugate (ADC) #Collaboration #Partnership

Antibody development drives high-value biotech deals

The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature.1 Using data provided by DealForma for the period 1 January 2022 to 16 June 2023, Nature analysed the deal trends in the field. In 2022, there were 156 antibody-focused deals with… Read More

#Editor's Choice #Market Reports #News

DDW Antibodies eBook
#Antibodies #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Drug development #Drug discovery

Antibody discovery: Breakthroughs accelerating therapeutic antibodies

This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector. Download this exclusive eBook to learn more about: The market for therapeutic antibodies Advancements and challenges in the sector Trends in the antibody-drug conjugate (ADC) market… Read More

#DDW eBooks #Intelligence

Cancer Abnormal Cells Nucleus Genetic Division Infection Microscope
#Antibody drug conjugate (ADC) #Biocytogen Pharmaceuticals #License agreement #Pheon Therapeutics #Therapeutic Antibodies

Licence agreement to develop ADCs for hard-to-treat cancers 

Pheon Therapeutics, an antibody drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has entered an exclusive licence agreement with Biocytogen Pharmaceuticals, a global biotech company focused on the discovery of novel antibody therapeutics.   Under the terms of the agreement, Pheon… Read More

#News

Drug discovery concept petri dish
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Join this exclusive DDW roundtable on drug discovery trends

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News